Merck, Ridgeback Launch Phase 3 Trial of Covid-19 Prophylactic
September 01 2021 - 7:30AM
Dow Jones News
By Matt Grossman
Merck & Co. and Ridgeback Biotherapeutics LP said they are
launching a Phase 3 trial of molnupiravir, an antiviral drug it is
investigating for post-exposure prevention of Covid-19.
The trial will enroll about 1,300 participants who live with
someone who has been diagnosed with Covid-19. Some participants
will get an oral dose of the drug every 12 hours for five days,
while the others will get a placebo, the companies said.
The primary endpoints are the percentage of people who get
Covid-19, the percentage of people with an adverse event and the
percentage of people who discontinued the study because of an
adverse event, the companies said.
Participants will be drawn from countries on five continents in
the international trial, they said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
September 01, 2021 07:15 ET (11:15 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
